1. Home
  2. Directory
  3. California
  4. Palo Alto
  5. Podiatrist
  6. NPI Profile
  7. Prescriptions 1013971621

ELIZABETH ANNE REILLY DPM
Prescription History 1013971621
Podiatrist in Palo Alto, CA


Quality Rating: 76.5 out of 100 score

NPI Status: Active since April 12, 2006

Contact Information

300 PASTEUR DR
PALO ALTO, CA
ZIP 94305
Phone: (650) 723-4000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ELIZABETH ANNE REILLY DPM, an active Podiatrist specialist practicing in Palo Alto, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 80 documented patient claims. Among these therapy options, the most frequently utilized medication is Ciclopirox, which accounts for 31 claims alone.

Medication Index

C
E
S
No matching medications currently found on file.

Ciclopirox

Generic Formulation: CiclopiroxSpecialty: Podiatry
Provider Metrics Summary
Total Claims 31
30-Day Fills 37.0
Days Supply 1,110
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply965
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,154.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.24

State Avg Cost Per Claim

$36.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane and pyridinone derivative that is used for the treatment of fungal infections of the skin and nails, and for treatment of VAGINAL YEAST INFECTIONS.

Therapeutic Applications

This medication is used to treat fungal infections of the fingernails and toenails. It is used as part of a treatment program that may include the removal of unattached, infected nails by a health care professional. Ciclopirox works by stopping the growth of fungus.

Econazole Nitrate

Generic Formulation: Econazole NitrateSpecialty: Podiatry
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 458
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply773
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $672.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.88

State Avg Cost Per Claim

$96.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazole derivative that is commonly used as a topical antifungal agent.

Therapeutic Applications

Econazole is used to treat a variety of fungal skin infections such as athlete's foot, jock itch, and ringworm. This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Econazole is an azole antifungal that works by preventing the growth of fungus.

Silver Sulfadiazine

Generic Formulation: Silver SulfadiazineSpecialty: Podiatry
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 284
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills22.1
Peer Average Days Supply514
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $107.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.96

State Avg Cost Per Claim

$13.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial used topically in burn therapy.

Therapeutic Applications

This medication is used with other treatments to help prevent and treat wound infections in patients with serious burns. Silver sulfadiazine works by stopping the growth of bacteria that may infect an open wound. This helps to decrease the risk of the bacteria spreading to surrounding skin, or to the blood where it can cause a serious blood infection (sepsis). Silver sulfadiazine belongs to a class of drugs known as sulfa antibiotics. Silver sulfadiazine must not be used on premature babies or on newborns during the first 2 months of life because of the risk of serious side effects.

Ssd

Generic Formulation: Silver SulfadiazineSpecialty: Podiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 271
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.9
Peer Average Days Supply600
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $131.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.92

State Avg Cost Per Claim

$19.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial used topically in burn therapy.

Therapeutic Applications

This medication is used with other treatments to help prevent and treat wound infections in patients with serious burns. Silver sulfadiazine works by stopping the growth of bacteria that may infect an open wound. This helps to decrease the risk of the bacteria spreading to surrounding skin, or to the blood where it can cause a serious blood infection (sepsis). Silver sulfadiazine belongs to a class of drugs known as sulfa antibiotics. Silver sulfadiazine must not be used on premature babies or on newborns during the first 2 months of life because of the risk of serious side effects.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ELIZABETH ANNE REILLY DPM provides transparency into local medical care patterns within Palo Alto, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Podiatrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.